Who are Cardiff Oncology, Inc.'s main suppliers?

Cardiff Oncology, Inc. (CRDF) key suppliers include: CLINICAL-RESEARCH-ORGANIZATIONS, INVESTIGATORS, NERVIANO, PROFESSIONAL-SERVICE-PROVIDERS, NERVIANO-MEDICAL-SCIENCES-S-R-L and 2 more. View the full supplier network at chainsifter.com/chain/CRDF.

Who are Cardiff Oncology, Inc.'s major customers?

Cardiff Oncology, Inc. (CRDF) key customers include: PFIZER-INC, PFIZER-IGNITE. View the full customer network at chainsifter.com/chain/CRDF.

What sector is Cardiff Oncology, Inc. in?

Cardiff Oncology, Inc. (CRDF) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CRDF Supply Chain: Cardiff Oncology, Inc. Supplier List & 12 Relationships

7Suppliers

2Customers

3Debt Items

6Related Chains

Cardiff Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CLINICAL-RESEARCH-ORGANIZATIONS	CLINICAL-RESEARCH-ORGANIZATIONS	92%	The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
INVESTIGATORS	INVESTIGATORS	92%	The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
NERVIANO	NERVIANO	92%	In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which the Company refers to as onvansertib.
PROFESSIONAL-SERVICE-PROVIDERS	PROFESSIONAL-SERVICE-PROVIDERS	92%	The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
NERVIANO-MEDICAL-SCIENCES-S-R-L	NERVIANO-MEDICAL-SCIENCES-S-R-L	90%	the Company was informed in writing by NMS that NMS was terminating the Agreement pursuant to Section 11.3 of the Agreement
PFIZER-IGNITE	PFIZER-IGNITE	90%	The trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies.
TROVAGENE-INC	TROVAGENE-INC	85%	10.10 Form of Seventh Amendment to Standard Industrial Net Lease dated April 4, 2016 between Trovagene, Inc. and BMR-Coast 9 LP

Cardiff Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
PFIZER-INC	PFIZER-INC	92%	10.14 @ Development Agreement between Cardiff Oncology, Inc. and Pfizer, Inc. dated June 30, 2023
PFIZER-IGNITE	PFIZER-IGNITE	85%	The trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies.

Cardiff Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CRDF-DEBT-8843	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-12-31.
CRDF-DEBT	Debt stack $646,000	90%	Market cache reports total debt of $646,000.
CRDF-DEBT-8842	Warrants outstanding: 2213115	90%	xbrl warrant detail from xbrl 2025-12-31.

Cardiff Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cardiff Oncology, Inc..

Cardiff Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
CRDF-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 116 tracked holders.

Cardiff Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
TLSA	Tiziana Life Sciences Ltd	100.00	2
HEPA	Hepion Pharmaceuticals, Inc.	100.00	2
SIGA	SIGA Technologies, Inc.	100.00	2
IMRN	Immuron Limited	100.00	2
TMC	TMC the metals company Inc.	50.00	2
OKYO	OKYO Pharma Limited	36.29	1	['spend']

Cardiff Oncology, Inc. Supply Chain